DDInter1476 DDInter606
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Droxidopa is a precursor of noradrenaline that is used in the treatment of Parkinsonism. It is approved for use in Japan and is currently in trials in the U.S. The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension. There is a deficit of noradrenaline as well as of dopamine in Parkinson's disease and it has been proposed that this underlies the sudden transient freezing seen usually in advanced disease. Though L-DOPS has been used in Japan and Southeast Asia already for some time, it is also currently in clinical trials at the phase III point in the United States (U.S.), Canada, Australia, and throughout Europe. Provided L-DOPS successfully completes clinical trials, it could be approved for the treatment of neurogenic orthostatic hypotension (NOH) as early as 2011. Additionally, phase II clinical trials for intradialytic hypotension are also underway. Chelsea Therapeutics obtained orphan drug status (ODS) for L-DOPS in the U.S. for NOH, and that of which associated with Parkinson's disease , pure autonomic failure, and multiple system atrophy, and is the pharmaceutical company developing it in that country.
Pirbuterol {u} (Compound) resembles {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Droxidopa
Pirbuterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Droxidopa
Pirbuterol {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Droxidopa
Pirbuterol {u} (Compound) resembles {v} (Compound) Epinephrine
Epinephrine {u} (Compound) resembles {v} (Compound) Levonordefrin
Levonordefrin {u} (Compound) resembles {v} (Compound) Droxidopa
Pirbuterol {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Droxidopa
Pirbuterol {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Droxidopa
Pirbuterol {u} (Compound) causes {v} (Side Effect) Shock
Shock {u} (Side Effect) is caused by {v} (Compound) Mesalazine
Mesalazine {u} (Compound) resembles {v} (Compound) Droxidopa
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Bupranolol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Droxidopa
Pirbuterol {u} (Compound) resembles {v} (Compound) Salbutamol
Salbutamol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Droxidopa
Pirbuterol {u} (Compound) resembles {v} (Compound) Epinephrine
Epinephrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levodopa
Levodopa {u} (Compound) resembles {v} (Compound) Droxidopa
Pirbuterol (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa
Pirbuterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Droxidopa (Compound)
Pirbuterol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Droxidopa (Compound)
Pirbuterol (Compound) resembles Epinephrine (Compound) and Epinephrine (Compound) resembles Levonordefrin (Compound) and Levonordefrin (Compound) resembles Droxidopa (Compound)
Pirbuterol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa
Pirbuterol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa
Pirbuterol (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Mesalazine (Compound) and Mesalazine (Compound) resembles Droxidopa (Compound)
Pirbuterol (Compound) resembles Bupranolol (Compound) and Bupranolol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa
Pirbuterol (Compound) resembles Salbutamol (Compound) and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Droxidopa
Pirbuterol (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Levodopa and Levodopa (Compound) resembles Droxidopa (Compound)